Literature DB >> 8243793

Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma.

L Sichletidis1, E Daskalopoulou, G Kyriazis, I Kosmidou, S Koupidou, T Pechlivanidis, D Chloros.   

Abstract

This study compared the protection provided by salbutamol and salmeterol against exercise-induced asthma. Asthmatic patients (n = 12) with exercise-induced asthma were exercised submaximally for 6 min on a treadmill 1, 6 and 12 h after inhalation of 200 micrograms salbutamol or 50 micrograms salmeterol. Each patient also took baseline exercise 1 h after two puffs of placebo. Two days later the drugs were administered in a double-blind trial of crossover design with an interval of 48 h between the two treatments. The main parameters measured were: air flow with a Wright flowmeter and mediator concentrations (histamine, leucotriene and prostaglandin D2 measured by radioimmunoassay) in venous blood, which was withdrawn before and 4 min after each exercise period. The maximum percentage bronchoconstriction recorded following placebo was 29 +/- 4% and following salbutamol inhalation it was 4 +/- 4%, 20 +/- 13%, 27 +/- 10%, respectively, for the exercise periods performed 1, 6 and 12 h after inhalation of the drug. Following salmeterol, the corresponding figures were 3 +/- 4%, 3 +/- 3% and 11 +/- 9%. The concentrations of mediator in plasma were significantly increased after exercise. Salbutamol and salmeterol intake reduced these concentrations both when the patients were at rest and following the exercise period. This effect of both drugs on the mediators corresponded with the protection they provided against exercise-induced asthma and was maintained for 12 h after salmeterol inhalation and for 6 h after salbutamol inhalation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243793     DOI: 10.1177/030006059302100203

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 2.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 4.  Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options.

Authors:  Tomasz Grzelewski; Iwona Stelmach
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

5.  An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm.

Authors:  D S Pearlman; William Rees; Kendyl Schaefer; Holly Huang; William T Andrews
Journal:  J Asthma       Date:  2007-11       Impact factor: 2.515

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.